Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
Cell sorting technology supports researchers advancing new therapies
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
GMP-compliant documentation of all manufacturing steps for cell and gene therapies
Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities.
Subscribe To Our Newsletter & Stay Updated
